Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 1
2005 6
2006 3
2007 3
2008 1
2009 3
2010 9
2011 8
2012 8
2013 7
2014 2
2015 6
2016 6
2017 4
2018 2
2019 3
2020 9
2021 14
2022 10
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Clinicopathological prognostic characteristics and long‑term outcomes of patients with breast cancer and collagen disorder in comparison to those without collagen disorder.
Matsuura K, Osaki A, Ichinose Y, Fujimoto A, Sakakibara A, Nukui A, Yokogawa H, Shimada H, Asano A, Ohara M, Ishiguro H, Takahashi T, Saeki T. Matsuura K, et al. Among authors: osaki a. Oncol Lett. 2023 Sep 29;26(5):495. doi: 10.3892/ol.2023.14082. eCollection 2023 Nov. Oncol Lett. 2023. PMID: 37854859 Free PMC article.
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE, Masuda N, Mukohara T, Takahashi S, Nakayama T, Inoue K, Iwata H, Yamamoto Y, Alvarez RH, Toyama T, Takahashi M, Osaki A, Saji S, Sagara Y, O'Shaughnessy J, Ohwada S, Koyama K, Inoue T, Li L, Patel P, Mostillo J, Tanaka Y, Sternberg DW, Sellami D, Yonemori K. Krop IE, et al. Among authors: osaki a. J Clin Oncol. 2023 Dec 20;41(36):5550-5560. doi: 10.1200/JCO.23.00882. Epub 2023 Oct 6. J Clin Oncol. 2023. PMID: 37801674 Free PMC article. Clinical Trial.
Vimentin-positive invasive breast carcinoma of no special type: A breast carcinoma with lethal biological characteristics.
Ichinose Y, Hasebe T, Hirasaki M, Sakakibara A, Yokogawa H, Nukui A, Hiratsuka M, Fujimoto A, Iso C, Wakui N, Shibasaki S, Kamada K, Suzuki N, Kamakura Y, Yasuda M, Aya A, Shimada H, Matsuura K, Ishiguro H, Osaki A, Saeki T. Ichinose Y, et al. Among authors: osaki a. Pathol Int. 2023 Sep;73(9):413-433. doi: 10.1111/pin.13350. Epub 2023 Jun 28. Pathol Int. 2023. PMID: 37378453
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Two Cases of Gastric Varices with Left-sided Portal Hypertension Due to Essential Thrombocythemia Treated with Gastric Devascularization or Partial Splenic Embolization.
Watanabe Y, Osaki A, Yamazaki S, Yokoyama H, Takaku K, Sato M, Sato D, Yokoyama N, Waguri N, Terai S. Watanabe Y, et al. Among authors: osaki a. Intern Med. 2023 Oct 1;62(19):2839-2846. doi: 10.2169/internalmedicine.1273-22. Epub 2023 Feb 22. Intern Med. 2023. PMID: 36823082 Free PMC article.
Correction to: Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast.
Hiratsuka M, Hasebe T, Ichinose Y, Sakakibara A, Fujimoto A, Wakui N, Shibasaki S, Hirasaki M, Yasuda M, Nukui A, Shimada H, Yokogawa H, Matsuura K, Hojo T, Osaki A, Saeki T. Hiratsuka M, et al. Among authors: osaki a. Virchows Arch. 2022 Dec 29. doi: 10.1007/s00428-022-03486-2. Online ahead of print. Virchows Arch. 2022. PMID: 36580139 No abstract available.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
106 results